SCPS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCPS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Scopus BioPharma's Trailing 12-Month Free Cash Flow is $-3.04 Mil, and Market Cap is $0.09 Mil. Therefore, Scopus BioPharma's FCF Yield % for today is -3,457.95%.
The historical rank and industry rank for Scopus BioPharma's FCF Yield % or its related term are showing as below:
Scopus BioPharma's FCF Margin % for the quarter that ended in Jun. 2023 was 0.00%.
The historical data trend for Scopus BioPharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scopus BioPharma Annual Data | |||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
FCF Yield % | Get a 7-Day Free Trial | - | - | -1.17 | -33.13 | -395.25 |
Scopus BioPharma Quarterly Data | ||||||||||||||||||||
Jun18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
FCF Yield % | Get a 7-Day Free Trial | -126.83 | -66.73 | -82.07 | -126.42 | -177.60 |
For the Biotechnology subindustry, Scopus BioPharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Scopus BioPharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Scopus BioPharma's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Scopus BioPharma's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -8.129 | / | 2.05669425 | |
= | -395.25% |
Scopus BioPharma's annualized FCF Yield % for the quarter that ended in Jun. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -1.009 | * | 4 | / | 2.2725522 | |
= | -177.60% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scopus BioPharma FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Scopus BioPharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Ira Scott Greenspan | director | 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106 |
Joshua R Lamstein | director, officer: Chairman | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170 |
Alan M Horsager | officer: See Remarks | 1021 N EVERETT STREET, GLENDALE CA 91207 |
Robert J Gibson | director, officer: Vice Chairman | 71 LANTERN RIDGE RD, NEW CANAAN CT 06840 |
Lesley Russell | director | 41 MOORES RD., FRAZER PA 19355 |
Iv David Weild | director | 22 ORIOLE AVENUE, BRONXVILLE NY 10708 |
David S. Battleman | director | C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019 |
David A. Buckel | director | SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601 |
Raphael Hofstein | director | C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120 |
Paul Hopper | director | 7982 DOUG HILL, SAN DIEGO CA 92127 |
Ashish P Sanghrajka | director, officer: President | 101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005 |
From GuruFocus
By Marketwired Marketwired • 10-08-2021
By Marketwired Marketwired • 09-22-2021
By GuruFocusNews GuruFocusNews • 03-23-2022
By GuruFocusNews GuruFocusNews • 05-05-2022
By GuruFocusNews GuruFocusNews • 12-17-2021
By GuruFocusNews GuruFocusNews • 01-10-2022
By GuruFocusNews GuruFocusNews • 12-07-2021
By PRNewswire PRNewswire • 01-06-2022
By PRNewswire PRNewswire • 12-06-2021
By Marketwired Marketwired • 10-05-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.